JP2010270123A - Hivプロテアーゼ阻害性化合物の製造方法 - Google Patents
Hivプロテアーゼ阻害性化合物の製造方法 Download PDFInfo
- Publication number
- JP2010270123A JP2010270123A JP2010150808A JP2010150808A JP2010270123A JP 2010270123 A JP2010270123 A JP 2010270123A JP 2010150808 A JP2010150808 A JP 2010150808A JP 2010150808 A JP2010150808 A JP 2010150808A JP 2010270123 A JP2010270123 A JP 2010270123A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- thiazolyl
- methyl
- methoxycarbonyl
- diphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
- -1 anhydride derivative of N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine Chemical class 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 28
- 150000002148 esters Chemical class 0.000 claims abstract description 16
- 239000002253 acid Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- HBPTXDXGWDVDON-BVSLBCMMSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,5s)-5-amino-3-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@@H](N)CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)C1=CC=CC=C1 HBPTXDXGWDVDON-BVSLBCMMSA-N 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 150000008064 anhydrides Chemical class 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- TZFSTJAMNQSGNG-UHFFFAOYSA-N 1,3-thiazol-5-ylmethyl n-(3-hydroxy-1,6-diphenylhexyl)carbamate Chemical compound C=1N=CSC=1COC(=O)NC(C=1C=CC=CC=1)CC(O)CCCC1=CC=CC=C1 TZFSTJAMNQSGNG-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 5
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 3
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- OSQWRZICKAOBFA-LLVKDONJSA-N (2r)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)N(C)CC1=CSC(C(C)C)=N1 OSQWRZICKAOBFA-LLVKDONJSA-N 0.000 claims description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 claims 2
- OAVJZYLYQRFWMO-UHFFFAOYSA-N 1,1-diphenylhexan-3-ol Chemical compound C=1C=CC=CC=1C(CC(O)CCC)C1=CC=CC=C1 OAVJZYLYQRFWMO-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 3
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 108010010369 HIV Protease Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- OSQWRZICKAOBFA-NSHDSACASA-N (2s)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)N(C)CC1=CSC(C(C)C)=N1 OSQWRZICKAOBFA-NSHDSACASA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- NCDNCNXCDXHOMX-OOUBJREFSA-N 1,3-thiazol-5-ylmethyl n-[(2s,3s,5s)-3-hydroxy-5-[[(2r)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate Chemical compound N([C@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-OOUBJREFSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 2
- 108010016191 Human immunodeficiency virus 2 p16 protease Proteins 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 2
- 229910000071 diazene Inorganic materials 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MWQKEJVVWBQIOO-UHFFFAOYSA-N (4-nitrophenyl) 1,3-thiazol-5-ylmethyl carbonate;hydrochloride Chemical compound Cl.C1=CC([N+](=O)[O-])=CC=C1OC(=O)OCC1=CN=CS1 MWQKEJVVWBQIOO-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- YSGCCSOQILPWFS-UHFFFAOYSA-N 2-methylpropyl 1-(2-methylpropoxy)-2h-quinoline-2-carboxylate Chemical compound C1=CC=C2N(OCC(C)C)C(C(=O)OCC(C)C)C=CC2=C1 YSGCCSOQILPWFS-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 0 CC=N[C@](c1c(C)c(CC=C(*)*(*)=*)c[n]1)NC Chemical compound CC=N[C@](c1c(C)c(CC=C(*)*(*)=*)c[n]1)NC 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UKFHOTNATOJBKZ-ACRUOGEOSA-N tert-butyl n-[(2s,4s,5s)-5-amino-4-hydroxy-1,6-diphenylhexan-2-yl]carbamate Chemical compound C([C@H](N)[C@@H](O)C[C@@H](NC(=O)OC(C)(C)C)CC=1C=CC=CC=1)C1=CC=CC=C1 UKFHOTNATOJBKZ-ACRUOGEOSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003679 valine derivatives Chemical class 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
【解決手段】N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−Lーバリンの混合無水物誘導体を、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリンの活性化エステル誘導体に変換し、その後、該活性化エステルを(2S,3S,5S)−5−アミノ−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンと反応させることからなる製造方法。
【選択図】なし
Description
の化合物がHIV−1およびHIV−2プロテアーゼの阻害剤として特に有用であり、HIVプロテアーゼを試験管内でおよび生体内で阻害するために有用であり、またHIV感染を防止するために有用である、ということも最近知見された。
本発明は、(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン(化合物III)および(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン(化合物IV)の製造方法に関する。該方法は、図式IIIに示されている。該方法は、中間体を単離することなく行われる3つの工程からなる。
例1
(2S,3S,5S)−5−アミノ−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン
750ガロンのガラス内張り反応器に、(2S,3S,5S)−2−アミノ−3−ヒドロキシ−5−(t−ブチルオキシカルボニルアミノ)−1,6−ジフェニルヘキサン・0.5コハク酸塩(75.0kg,169モル)、5−(p−ニトロフェニルオキシカルボニルオキシメチル)チアゾール塩酸塩(65.0kg,205モル)および重炭酸ナトリウム(70.0kg,833モル)を装填した。エチルアセテート(826kg,918L)を添加し、かきまぜ機を始動させた。水道水(788kg)を添加し、この混合物を30℃に温め、固体のすべてが溶解するまで2.5時間撹拌した。30分間静置した後、水性層を分離しそして捨てた。有機層を60℃に温め、12時間撹拌した。次いでこの溶液を30℃に冷却し、28%アンモニア水(9.0kg,148モル)を添加した。この混合物を、25〜30℃にて3時間撹拌した。この混合物を3回10%炭酸カリウム水溶液(各回903kg)で洗浄した。水性層を、各洗浄後排出し、捨てた。このエチルアセテート溶液に濃塩酸(59.0kg,600モル)を添加し、50℃に温めると共に3時間撹拌した。
(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン
750ガロンのガラス内張り反応器に、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリン(57.0kg,182モル)およびエチルアセテート(916kg,1018L)を装填した。この混合物をすべてが溶解するまで撹拌し、次いでこの反応器にN−メチルモルホリン(28.0kg,277モル)を装填し、生じた溶液を−18℃に冷却した。エチルアセテート(101kg,112L)中のイソブチルクロロホルメート(24.4kg,180モル)の溶液を、別個の反応器中で調製した。このイソブチルクロロホルメート溶液を、上記のように調製したバリン誘導体およびN−メチルモルホリンの冷溶液中に、温度を−18℃と−14℃の間に維持しながら装入した。−14℃にて約30分間撹拌した後、この混合物にN−ヒドロキシスクシンイミド(21.2kg,184モル)を添加した。更に30分間撹拌した後、この混合物を約0℃に温め、約1時間撹拌した。
m.p.121〜123℃。
1H−NMR:(CD3OD,300MHz)δ7.78〜7.96(m,1H)、7.85(s,1H)、7.07〜7.33(m,11H)、6.68〜6.75(m,1H)、6.17〜6.28(m,1H)、5.22(s,2H)、4.47〜4.67(m,2H)、4.32〜4.45(m,1H)、3.98〜4.10(m,2H)、3.72〜3.82(m,1H)、3.28〜3.40(m,1H)、3.02(s,3H)、2.67〜2.92(m,4H)、1.92〜2.08(m,1H)、1.56〜1.80(m,2H)、1.37〜1.46(m,6H)、0.84〜0.96(m,6H)。
13C−NMR:(CD3OD,75MHz)δ176.0、169.8、155.7、153.7、152.4、149.3、139.3、139.2、135.8、135.2、126.3、126.0、124.9、124.8、122.9、122.8、111.2、111.1、66.5、57.6、57.5、54.5、52.9、52.8、45.4、37.3、35.7、34.9、30.9、30.0、27.7、19.3、19.2、15.7、14.5。
(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン
N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリンをN−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリンで置き換えて例2の処理操作に従って、標題化合物を製造する。
m.p.68〜69℃。
1H−NMR:(DMSO−d6)δ0.56(d,J=6Hz,3H)、0.63(d,J=6Hz,3H)、1.28(d,J=7Hz,6H)、1.47(m,2H)、1.77(8重線,J=6Hz,1H)、2.5〜2.7(m,4H)、2.85(s,3H)、3.20(7重線,J=7Hz,1H)、3.4(m,1H)、3.6(m,1H)、3.90(dd,J=8.6Hz,1H)、3.93(m,1H)、4.43(AA′,2H)、4.65(d,J=6Hz,1H)、5.15(AA′,2H)、6.02(幅広いd,J=9Hz,1H)、6.90(幅広いd,J=9Hz,1H)、7.1〜7.2(m,11H)、7.70(幅広いd,J=9Hz,1H)、7.85(s,1H)、9.04(s,1H)。質量スペクトル:(M+H)+=721。
(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンの別の製造法
撹拌機、窒素雰囲気、60mLの側腕添加漏斗および熱電対を備えた250mLの四口丸底フラスコに、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリン(5.03g,16ミリモル)およびエチルアセテート(93mL)を装填した。この混合物を固体のすべてが溶解するまで撹拌し、次いで−15℃に冷却した。この冷却された溶液に、N−メチルモルホリン(1.77ML,16ミリモル)を添加した。この混合物を−18℃に冷却した。エチルアセテート(8mL)中のイソブチルクロロホルメート(2.08mL,16ミリモル)を、反応混合物の温度を−14.5℃未満に維持しながら添加した。−17℃にて1時間撹拌した後、1−ヒドロキシベンゾトリアゾール(2.46g,16ミリモル)を一度に添加した。生じたスラリーを0℃に温め、0℃以下に維持しながらエチルアセテート(25mL)中の(2S,3S,5S)−5−アミノ−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサン(6.4g,15ミリモル)を添加した。生じた混合物を0℃にて1時間撹拌し、次いで室温に温めそして15時間撹拌した。この反応混合物に、75mLの5%水性重炭酸ナトリウムを添加した。有機層を分離し、75mLの5%水性重炭酸ナトリウムで再び洗浄した後、各回75mLの10%水性クエン酸で2回そして最後に75mLの水で洗浄した。溶媒を真空下で除去し、残渣を270mLの1:1のヘプタン/エチルアセテートから結晶化させて、9.25gの所望生成物を得た。
(2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンの別の製造法
3リットルのフラスコ中で、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリン(196.6g,0.627ミリモル)と1−ヒドロキシベンゾトリアゾール(107g,0.701モル)とTHF(1.6L)とを混合した。THF(200mL)中のジシクロヘキシルカルボジイミド(129.4g,0.627モル)の溶液を一度に添加した。生じた混合物を、室温にて一晩撹拌した。
Claims (8)
- (2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンまたはその酸付加塩の製造方法であって、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−Lバリンの混合無水物誘導体をN−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリンの活性化エステル誘導体に変換し、その後該活性化エステルを(2S,3S,5S)−5−アミノ−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンと反応させることからなる上記方法。
- 式
の化合物をR★★OH(式中、R★★はスクシンイミド−1−イル、ベンゾトリアゾール−1−イル、フタルイミド−1−イル、5−ノルボルネン−2,3−ジカルボキシミジル、キノリン−8−イル、1,2,3−ベンゾトリアジン−4(3H)−オン−3−イル、ピペリジン−1−イル、ペンタクロロフェニル、2,4,5−トリクロロフェニル、2−ニトロフェニル、4−ニトロフェニルおよびペンタフルオロフェニルから成る群から選択される。)と反応させて、式
- (2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−L−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンまたはその酸付加塩の製造方法であって、式
の化合物をR★★OH(式中、R★★はスクシンイミド−1−イルである。)と反応させて、式
- (2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンまたはその酸付加塩の製造方法であって、N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリンの混合無水物誘導体をN−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリンの活性化エステル誘導体に変換し、その後該活性化エステルを(2S,3S,5S)−5−アミノ−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンと反応させることからなる上記方法。
- 式
の化合物をR★★OH(式中、R★★はスクシンイミド−1−イル、ベンゾトリアゾール−1−イル、フタルイミド−1−イル、5−ノルボルネン−2,3−ジカルボキシミジル、キノリン−8−イル、1,2,3−ベンゾトリアジン−4(3H)−オン−3−イル、ピペリジン−1−イル、ペンタクロロフェニル、2,4,5−トリクロロフェニル、2−ニトロフェニル、4−ニトロフェニルおよびペンタフルオロフェニルから成る群から選択される。)と反応させて、式
- (2S,3S,5S)−5−(N−(N−((N−メチル−N−((2−イソプロピル−4−チアゾリル)メチル)アミノ)カルボニル)−D−バリニル)アミノ)−2−(N−((5−チアゾリル)メトキシカルボニル)アミノ)−1,6−ジフェニル−3−ヒドロキシヘキサンまたはその酸付加塩の製造方法であって、式
の化合物をR★★OH(式中、R★★はスクシンイミド−1−イルである。)と反応させて、式
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/469,965 | 1995-06-06 | ||
US08/469,965 US5567823A (en) | 1995-06-06 | 1995-06-06 | Process for the preparation of an HIV protease inhibiting compound |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50055497A Division JP4580044B2 (ja) | 1995-06-06 | 1996-05-13 | Hivプロテアーゼ阻害性化合物の製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010270123A true JP2010270123A (ja) | 2010-12-02 |
JP5390477B2 JP5390477B2 (ja) | 2014-01-15 |
Family
ID=23865732
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50055497A Expired - Lifetime JP4580044B2 (ja) | 1995-06-06 | 1996-05-13 | Hivプロテアーゼ阻害性化合物の製造方法 |
JP2010150808A Expired - Lifetime JP5390477B2 (ja) | 1995-06-06 | 2010-07-01 | Hivプロテアーゼ阻害性化合物の製造方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50055497A Expired - Lifetime JP4580044B2 (ja) | 1995-06-06 | 1996-05-13 | Hivプロテアーゼ阻害性化合物の製造方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5567823A (ja) |
EP (1) | EP0830353B1 (ja) |
JP (2) | JP4580044B2 (ja) |
AT (1) | ATE216696T1 (ja) |
CA (1) | CA2219983C (ja) |
DE (1) | DE69620882T2 (ja) |
DK (1) | DK0830353T3 (ja) |
ES (1) | ES2176456T3 (ja) |
MX (1) | MX9709454A (ja) |
PT (1) | PT830353E (ja) |
WO (1) | WO1996039398A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0727419T3 (da) | 1992-12-29 | 2002-06-10 | Abbott Lab | Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US6180634B1 (en) * | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
US6803466B1 (en) * | 1997-12-08 | 2004-10-12 | The Scripps Research Institute | HIV/FIV protease inhibitors having a small P3 residue |
WO1999029311A1 (en) * | 1997-12-08 | 1999-06-17 | The Scripps Research Institute | Hiv/fiv protease inhibitors having a small p3 residue |
MY121765A (en) * | 1998-07-20 | 2006-02-28 | Abbott Lab | Polymorph of ritonavir |
US6894171B1 (en) * | 1998-07-20 | 2005-05-17 | Abbott Laboratories | Polymorph of a pharmaceutical |
TR200103488T2 (tr) * | 1999-06-04 | 2002-04-22 | Abbott Laboratories | Geliştirilmiş farmasötik formülasyonlar. |
IT1313624B1 (it) * | 1999-09-21 | 2002-09-09 | Archimica Spa Ora Clariant Lif | Procedimento per la sintesi del ritonavir |
JP5767429B2 (ja) * | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
CA2395987C (en) * | 2000-01-19 | 2009-12-22 | Abbott Laboratories | Improved pharmaceutical formulations |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0401742B8 (pt) * | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
EP2308490A1 (en) * | 2005-12-30 | 2011-04-13 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
WO2008041176A2 (en) * | 2006-10-03 | 2008-04-10 | Ranbaxy Laboratories Limited | Process for the preparation of form i and form ii of ritonavir |
WO2008067164A2 (en) * | 2006-11-15 | 2008-06-05 | Abbott Laboratories | Solid pharmaceutical dosage formulations |
LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
CA2710679A1 (en) * | 2008-01-04 | 2009-07-16 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
CN101967130B (zh) * | 2010-07-02 | 2012-12-26 | 厦门市亨瑞生化有限公司 | 利托那韦中间体的合成方法 |
CN102786494B (zh) * | 2012-07-26 | 2016-01-06 | 合肥华方医药科技有限公司 | 利托那韦异构体杂质的合成研究及控制方法 |
IN2014CH00872A (ja) * | 2014-02-21 | 2015-08-28 | Mylan Lab Ltd | |
CN104311503B (zh) * | 2014-11-03 | 2017-01-25 | 东北制药集团股份有限公司 | 一种制备抗hiv药物利托那韦的方法 |
CN111646953A (zh) * | 2020-04-23 | 2020-09-11 | 厦门蔚嘉制药有限公司 | 一种合成利托那韦的新方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014436A1 (en) * | 1992-12-29 | 1994-07-07 | Abbott Laboratories | Retroviral protease inhibiting compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
-
1995
- 1995-06-06 US US08/469,965 patent/US5567823A/en not_active Expired - Lifetime
-
1996
- 1996-05-13 DE DE69620882T patent/DE69620882T2/de not_active Expired - Lifetime
- 1996-05-13 EP EP96915755A patent/EP0830353B1/en not_active Expired - Lifetime
- 1996-05-13 PT PT96915755T patent/PT830353E/pt unknown
- 1996-05-13 CA CA002219983A patent/CA2219983C/en not_active Expired - Lifetime
- 1996-05-13 JP JP50055497A patent/JP4580044B2/ja not_active Expired - Lifetime
- 1996-05-13 DK DK96915755T patent/DK0830353T3/da active
- 1996-05-13 MX MX9709454A patent/MX9709454A/es active IP Right Grant
- 1996-05-13 AT AT96915755T patent/ATE216696T1/de active
- 1996-05-13 WO PCT/US1996/006812 patent/WO1996039398A1/en active IP Right Grant
- 1996-05-13 ES ES96915755T patent/ES2176456T3/es not_active Expired - Lifetime
-
2010
- 2010-07-01 JP JP2010150808A patent/JP5390477B2/ja not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014436A1 (en) * | 1992-12-29 | 1994-07-07 | Abbott Laboratories | Retroviral protease inhibiting compounds |
Non-Patent Citations (2)
Title |
---|
JPN4006022775; 社団法人 日本化学会: 第4版 実験化学講座22 有機合成IV -酸・アミノ酸・ペプチド- , 1992, pp. 258-271, 丸善株式会社 * |
JPN4006022776; JOHN JONES: The chemical synthesis of peptides , 1991, pp. 55-58, CLARENDON PRESS * |
Also Published As
Publication number | Publication date |
---|---|
PT830353E (pt) | 2002-10-31 |
DK0830353T3 (da) | 2002-07-29 |
JPH11507029A (ja) | 1999-06-22 |
JP5390477B2 (ja) | 2014-01-15 |
DE69620882D1 (de) | 2002-05-29 |
CA2219983C (en) | 2007-09-18 |
MX9709454A (es) | 1998-02-28 |
ATE216696T1 (de) | 2002-05-15 |
WO1996039398A1 (en) | 1996-12-12 |
EP0830353A1 (en) | 1998-03-25 |
JP4580044B2 (ja) | 2010-11-10 |
ES2176456T3 (es) | 2002-12-01 |
DE69620882T2 (de) | 2002-12-12 |
US5567823A (en) | 1996-10-22 |
EP0830353B1 (en) | 2002-04-24 |
CA2219983A1 (en) | 1996-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5390477B2 (ja) | Hivプロテアーゼ阻害性化合物の製造方法 | |
MXPA97009454A (en) | Procedure for the preparation of a compound to inhibit proteasa of the human immunodeficiency virus | |
KR100187990B1 (ko) | 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체 | |
CA2737055A1 (en) | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor | |
JP6307087B2 (ja) | ベンズアミド化合物の合成に有用な化合物 | |
WO2014057498A2 (en) | Process for the preparation of cobicistat intermediates | |
JP2019523273A (ja) | ベリノスタットの多形形態、およびその調製のためのプロセス | |
US10538507B2 (en) | Preparation process for high-purity dabigatran etexilate | |
JP3198416B2 (ja) | 抗ウイルス化合物類 | |
JP3723448B2 (ja) | チアゾリジンジオン誘導体の製造方法 | |
CZ276092A3 (en) | Heterocyclically substituted quinolylmethoxy-phenyl acetamides | |
EP0297641A1 (fr) | Composés guanidiniques comprenant un ion tétraphénylborate substitué, procédé d'obtention de ces composés et utilisation des composés lors de la synthése peptidique | |
MXPA97003766A (en) | Procedure for the preparation of 5-hydroxymethylene | |
US20040138232A1 (en) | Acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one having neuroleptic activity | |
JP2004528380A (ja) | ゾルピデムの製造方法 | |
CZ20032217A3 (cs) | Způsob výroby paroxetinu | |
JP2002500224A (ja) | 脱保護および再結晶法 | |
RU2826007C1 (ru) | Способ получения ритонавира | |
JP4307594B2 (ja) | 1−〔n2−((s−エトキシカルボニル)−3−フェニルプロピル)−n6−トリフルオロアセチル〕−l−リシル−l−プロリンの単離方法およびその単離生成物 | |
EP0280627B1 (fr) | Nouveaux dérivés N-substitués de l'alpha-mercaptométhyl benzène propanamide, leur procédé de préparation, leur application à titre de médicaments et les compositions les renfermant | |
RU2741389C1 (ru) | Способ получения промежуточного соединения для синтеза лекарственного средства | |
US6642388B1 (en) | Method for producing 2-aminomethyl-4-cyano-thiazol | |
JP6887022B2 (ja) | ケトライド化合物を製造するための方法 | |
KR20020067580A (ko) | 헤테로사이클릭 화합물의 제조방법 | |
WO2004069817A1 (en) | An improved process for preparing nizatidine intermediate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130131 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130625 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130701 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131001 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131010 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
EXPY | Cancellation because of completion of term |